Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $100.00

Prestige Consumer Healthcare (NYSE:PBH) had its price target boosted by Canaccord Genuity Group from $93.00 to $100.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $92.50.

Prestige Consumer Healthcare Stock Down 0.4 %

PBH stock opened at $86.96 on Friday. Prestige Consumer Healthcare has a 52 week low of $60.00 and a 52 week high of $88.36. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a 50-day simple moving average of $79.23 and a 200-day simple moving average of $75.48. The stock has a market capitalization of $4.30 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last ninety days. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Boston Trust Walden Corp purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $41,785,000. Raymond James Financial Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $42,593,000. Allspring Global Investments Holdings LLC grew its stake in shares of Prestige Consumer Healthcare by 19.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after buying an additional 255,045 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at $6,342,000. Finally, Millennium Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 565.1% in the 2nd quarter. Millennium Management LLC now owns 101,218 shares of the company’s stock valued at $6,969,000 after buying an additional 86,000 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.